Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis
- 1 June 1991
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 1 (3) , 129-133
- https://doi.org/10.1007/bf01625440
Abstract
Since osteoporotic fractures are mainly related to the diminution of the bone mineral density (BMD), the effect of pamidronate (3-amino-1-hydroxy-propylidene) 1,1-bisphosphonate on the BMD of the spine, proximal femur and radius shaft was evaluated in an initial cohort of 35 postmenopausal women with at least one vertebral fracture due to involutional osteoporosis. Pamidronate was given continuously during 18 months in a daily oral dose of 4.8 to 6.0 mg/kg supplemented with calcium (1 g/day). BMD — measured by dual photon absorptiometry — increased after one year 5.3±1.0% (PPP<0.001). The differing effects of pamidronate on the BMD of lumbar spine and proximal femur might be ascribed to dissimilarities between the proportions of trabecular and cortical bone in these. These results suggest that pamidronate may be prescribed to prevent fractures in cases of involutional osteoporosis with a significant decrease of BMD in lumbar spine and/or trochanter.Keywords
This publication has 30 references indexed in Scilit:
- Prevention of glucocorticoid-induced osteoporosisJournal of Bone and Mineral Research, 1990
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- New treatments for osteoporosisThe Lancet, 1990
- Changes in Bone Mass and Fracture Type in Patients With Hip FracturesPublished by Wolters Kluwer Health ,1989
- Bone density of the radius, spine, and proximal femur in osteoporosisJournal of Bone and Mineral Research, 1988
- Monitoring fluoride therapy in osteoporosis by dual photon absorptiometryBone, 1987
- Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancyBone, 1986
- The second hip fracture an epidemiologic studyActa Orthopaedica, 1986
- TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- The Treatment of Pagetʼs Bone Disease with Sodium EthidronateThe Lancet Healthy Longevity, 1979